LUCENCE/A*STAR
16.6.2020 12:02:06 CEST | Business Wire | Press release
Molecular diagnostics company Lucence and the Agency for Science, Technology and Research (A*STAR) today announced study results indicating that the reagent used in Lucence’s SAFER Sample saliva collection kit inactivates SARS-CoV-2 within 45 seconds of sample collection. This proprietary reagent also stabilizes viral RNA at room temperature for up to one week. Together, these properties enable accessible, non-invasive, and safe sample collection via saliva, which is critical to scaling cost-effective testing worldwide. The reagent used in Lucence’s SAFER Sample kit was invented at A*STAR’s Institute of Bioengineering and Nanotechnology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005320/en/
The SAFER Sample Collection Kit is registered as a Class A medical device with the Health Sciences Authority of Singapore and is an easy-to-use saliva collection kit that comes with a bottle of stabilization fluid to be mixed with the sample at the point of collection, keeping viral RNA stable at room temperature for up to one week. While conventional viral transport media requires cold-chain transport to prevent sample degradation, which can drive up associated costs and limit testing geography, SAFER Sample’s proprietary media means samples can be transported to a lab without the need for chilling.
In this new study, Lucence and A*STAR demonstrated that the proprietary reagent provided with the SAFER Sample kit also achieved complete inactivation of SARS-CoV-2 virus within 45 seconds of exposure. Conventional viral transport media used for collecting nasal and nasopharyngeal swab specimens do not inactivate viral samples, creating risk of exposure to active virus during transportation from collection sites to the laboratory and higher costs associated with biohazard handling procedures. SAFER Sample kit’s viral inactivation capabilities could mean enhanced safety and reduced risk of exposure for any individual involved in the collection, transport, and testing processes. Lucence worked with the Diagnostics Development (DxD) Hub of A*STAR to evaluate the virucidal properties of the SAFER Sample reagent. Duke-NUS Medical School was also engaged to perform the virucidal work with SARS-CoV-2 virus.
Mass testing and screening of large populations is key to reduce the risk of COVID-19 transmission, morbidity and mortality. By eliminating obstacles to sample integrity and, now, biosafety through viral inactivation, the SAFER Sample kit could expand testing geography, decrease associated costs, and increase efficiency of testing at scale compared to approaches utilizing conventional viral transport media.
Studies with clinical partners are ongoing to further evaluate the performance of the SAFER Sample kit. With the support of DxD Hub in verification and validation, quality management system (QMS), and regulatory registration, Lucence has received ISO13485:2016 certification for its QMS which controls the processes for the manufacture of the SAFER Sample Saliva Specimen Collection Kit.
About Lucence
Lucence is a precision oncology company that makes state-of-the-art, highly sensitive liquid biopsy tests for disease detection and treatment selection. Lucence is headquartered in Palo Alto and Singapore, and its services are delivered worldwide through an accredited central laboratory. Visit www.lucence.com for more information.
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency, spearheading economic-oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability. We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR’s R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg . For information on the Diagnostics Development (DxD) Hub, visit https://www.a-star.edu.sg/accelerate/innovation-offerings/diagnostics-development-hub
Follow us on Facebook | LinkedIn | Instagram | YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 13:00:00 CEST | Press release
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustatRecruitment completed in Phase 3 registrational study in patients with late-infantile and juvenile GM1/GM2 gangliosidosesEnrollment in Niemann-Pick type C disease (NPC) Phase 3 study is ongoingTopline data from GM1/GM2 gangliosidoses Phase 3 study is anticipated in early 2028 Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, invest
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds23.7.2026 13:00:00 CEST | Press release
Largest fundraise in the firm’s history brings total capital raised to more than $75 billion Francisco Partners (“FP”), a leading global investment firm that specializes in partnering with technology companies, today announced the closing of $21 billion in capital commitments across its Francisco Partners VIII, L.P. flagship fund and Francisco Partners Agility IV, L.P., its middle-market fund. FP exceeded its initial targets of $14.0 billion and $3.5 billion, respectively. This milestone builds on Francisco Partners' longstanding track record of performance, underscored by its distinction as the only firm to rank among the top three performers in each of the past six HEC-Dow Jones Large Buyout Performance Rankings.* “In our business, long-term success is created through a series of relationships built on years of trust and collaboration," said Dipanjan (“DJ”) Deb, Co-Founder and CEO of Francisco Partners. "We want to thank our investors for their support, our management teams for their
Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 10:21:00 CEST | Press release
The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 09:00:00 CEST | Press release
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom